Docoh
Loading...

LGND Ligand Pharmaceuticals

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Company profile

Ticker
LGND
Exchange
Website
CEO
John Higgins
Employees
Incorporated
Location
Fiscal year end
Former names
LIGAND PHARMACEUTICALS
SEC CIK
IRS number
770160744

LGND stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

23 Feb 21
11 Apr 21
31 Dec 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 47.96M 47.96M 47.96M 47.96M 47.96M 47.96M
Cash burn (monthly) 136.38M 2.03M (positive/no burn) (positive/no burn) (positive/no burn) (positive/no burn)
Cash used (since last report) 460.19M 6.84M n/a n/a n/a n/a
Cash remaining -412.23M 41.13M n/a n/a n/a n/a
Runway (months of cash) -3.0 20.3 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
22 Feb 21 Kozarich John W Common Stock Option exercise Aquire M No No 10.12 2,500 25.3K 29,708
22 Feb 21 Kozarich John W NQSO Common Stock Option exercise Dispose M No No 10.12 2,500 25.3K 4,835
15 Feb 21 Korenberg Matthew E Common Stock Payment of exercise Dispose F No No 172.46 969 167.11K 39,443
15 Feb 21 Korenberg Matthew E Common Stock Payment of exercise Dispose F No No 172.46 906 156.25K 40,412
15 Feb 21 Korenberg Matthew E Common Stock Payment of exercise Dispose F No No 172.46 434 74.85K 41,318
15 Feb 21 Higgins John L Common Stock Payment of exercise Dispose F No No 172.46 2,061 355.44K 337,848
15 Feb 21 Higgins John L Common Stock Payment of exercise Dispose F No No 172.46 1,947 335.78K 339,909
15 Feb 21 Higgins John L Common Stock Payment of exercise Dispose F No No 172.46 1,204 207.64K 341,856
15 Feb 21 Berkman Charles S Common Stock Payment of exercise Dispose F No No 172.46 442 76.23K 27,891
15 Feb 21 Berkman Charles S Common Stock Payment of exercise Dispose F No No 172.46 368 63.47K 28,333

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 233 248 -6.0%
Opened positions 29 31 -6.5%
Closed positions 44 42 +4.8%
Increased positions 80 89 -10.1%
Reduced positions 89 94 -5.3%
13F shares
Current Prev Q Change
Total value 2.29B 2.37B -3.3%
Total shares 22.7M 22.69M +0.0%
Total puts 793.5K 1.2M -33.6%
Total calls 281.6K 113.72K +147.6%
Total put/call ratio 2.8 10.5 -73.2%
Largest owners
Shares Value Change
William Blair Investment Management 2.04M $202.98M +7.7%
BLK Blackrock 1.97M $195.52M -8.0%
JHG Janus Henderson 1.61M $160.35M +0.4%
Vanguard 1.46M $145.09M +2.1%
Wasatch Advisors 1.17M $116.26M +4.9%
STT State Street 1.17M $115.9M +19.9%
Cardinal Capital Management 1.09M $108.23M +15.6%
MCQEF Macquarie 894.68K $88.98M +18.3%
Conestoga Capital Advisors 716.44K $71.25M +1.0%
Villere ST Denis J & Co 642.07K $63.85M -3.2%
Largest transactions
Shares Bought/sold Change
Victory Capital Management 5.91K -251.78K -97.7%
STT State Street 1.17M +193.76K +19.9%
SLFPF Standard Life Aberdeen 369.08K +172.09K +87.4%
BLK Blackrock 1.97M -170.11K -8.0%
GS Goldman Sachs 268.69K +165.15K +159.5%
Chicago Capital 332.85K -152.99K -31.5%
Cardinal Capital Management 1.09M +146.97K +15.6%
William Blair Investment Management 2.04M +145.67K +7.7%
MCQEF Macquarie 894.68K +138.55K +18.3%
Norges Bank 134.7K +134.7K NEW

Financial report summary

?
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AbCellera, abemaciclib, Accent, acid, Adalvo, Adept, affinity, AI, alfa, alia, allegedly, alliance, altogether, Alvogen, amide, AML, annex, appoint, appointed, Arabia, ASCEND, Asia, Asian, asparaginase, bacterium, batoclimab, Bayer, behavior, Beloteca, benchmark, BI, binding, bintrafusp, bioactivity, BLA, Bonsity, Bonteo, Brian, Buyer, Caldera, career, Carolina, carrier, CDK, CF, CFTR, chicken, choice, chose, chosen, Cipla, CNS, commonly, conjugate, conjugated, consortium, constitute, constituted, contact, correlate, cow, customizable, deep, delinquency, denied, denying, deprioritizing, diphtheria, discern, discrimination, discriminatory, distancing, Distinguished, doctrine, Dr, DUPLEX, durability, Durham, duty, earnout, EC, ELAINE, emerge, epidemic, EQRx, Erwinia, escalation, Eton, evolve, expert, feedback, fiduciary, fight, fisogatinib, flat, FORTEO, forum, founder, FPRE, fraudulently, Gavi, GE, GEM, gene, Genekey, globe, grow, growing, harassment, heat, Higuchi, HitGen, hospital, hospitalization, hotline, hydrolase, IgG, imposed, inapplicable, incentivizing, induced, Inst, Intelligence, interval, intramuscular, invasive, IP, irbesartan, Jazz, joint, Kangchen, kind, lab, leader, licensure, lifespan, linked, Livogiva, longest, loyalty, LTPTM, luminespib, Lundstrom, lymphoblastic, magnitude, Mainland, Malaysia, markedly, marker, MDS, MENA, meningococcal, micro, microbial, microcapillary, Minotaur, missed, molecular, morbidity, mutant, mutation, NaN, Neuritek, neurodegenerative, neurological, nonclinical, nonsense, nontransferable, NSCLC, obstructive, OmniTaur, OnKure, optica, ORR, output, outsourced, pain, paired, pandemic, Pandion, Pat, pathway, pause, peak, pegaspargase, Pelican, percent, Pfenex, pharmacodynamic, Phoenix, pMDI, pneumococcal, Pneumosil, posed, pre, premature, Prequalification, prevalent, Professor, prophylactic, protocol, proud, PTAB, pulmonary, rat, readthrough, recommended, redirecting, refusal, regorafenib, remission, reopening, retention, retirement, RHHBY, Roche, role, ROW, RTOR, RubrYc, salary, Saudi, SC, scalable, SCS, secondary, sensitive, sequencing, Serum, sexual, shock, SII, silico, Singapore, slightly, Smider, solubilize, spread, stack, staffing, Stanford, Stella, strive, subsidized, substance, sugemalimab, suggest, suitable, superior, suppression, Taiho, teclistamab, teriparatide, territory, Thailand, thereunder, thousand, toxin, tradename, transformative, transmembrane, travel, Travere, truncated, tuition, unresectable, unvested, usage, vaccine, Valentino, VALOR, Vaughn, Veklury, versatility, vivo, VOYAGE, waived, welfare, Wistar, withheld, xPloration, XRPro, zimberelimab
Removed: accumulation, ADHF, antibiotic, assured, averaged, avian, bioavailability, BMS, calculating, Capitsol, clarified, classification, combining, death, delafloxacin, Department, DUET, expiring, faster, fluoroquinolone, improving, inflammation, instrument, interpretation, interpretative, invoice, Journal, lived, maximize, MRSA, nondeductible, notably, principle, repertoire, revision, space, survival, uncollectible, Washington, week, wholly, wrong